Allergy Therapeutics plc (AIM:AGY)
London
· Delayed Price · Currency is GBP · Price in GBX 12.00
0.00 (0.00%)
At close: Feb 27, 2026
Allergy Therapeutics Income Statement
Financials in millions GBP. Fiscal year is July - June.
Millions GBP. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 55.04 | 55.2 | 59.59 | 72.77 | 84.33 | Upgrade
|
| Revenue Growth (YoY) | -0.28% | -7.36% | -18.11% | -13.71% | 7.83% | Upgrade
|
| Cost of Revenue | 25.74 | 25.46 | 26.34 | 23.26 | 22.11 | Upgrade
|
| Gross Profit | 29.3 | 29.74 | 33.25 | 49.51 | 62.23 | Upgrade
|
| Selling, General & Admin | 38.61 | 37.62 | 49.17 | 46.96 | 45.98 | Upgrade
|
| Research & Development | 15.38 | 22.9 | 20.12 | 15.66 | 12.89 | Upgrade
|
| Amortization of Goodwill & Intangibles | 0.56 | 0.53 | - | - | - | Upgrade
|
| Other Operating Expenses | -1.24 | -1.53 | -0.86 | -0.74 | -0.57 | Upgrade
|
| Operating Expenses | 57.79 | 64.07 | 68.43 | 61.88 | 58.3 | Upgrade
|
| Operating Income | -28.49 | -34.34 | -35.19 | -12.37 | 3.93 | Upgrade
|
| Interest Expense | -6.37 | -3.79 | -2.16 | -0.54 | -0.39 | Upgrade
|
| Interest & Investment Income | 0.38 | 0.29 | 0.33 | 0.25 | 0.11 | Upgrade
|
| Other Non Operating Income (Expenses) | -5.16 | -0.09 | - | 0 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -39.63 | -37.93 | -37.02 | -12.66 | 3.66 | Upgrade
|
| Merger & Restructuring Charges | - | -1.24 | - | - | - | Upgrade
|
| Other Unusual Items | 0.43 | - | -4.75 | - | - | Upgrade
|
| Pretax Income | -39.2 | -39.17 | -41.77 | -12.66 | 3.66 | Upgrade
|
| Income Tax Expense | 0.93 | -0.55 | 1.31 | 1.12 | 0.77 | Upgrade
|
| Net Income | -40.13 | -38.62 | -43.07 | -13.78 | 2.89 | Upgrade
|
| Net Income to Common | -40.13 | -38.62 | -43.07 | -13.78 | 2.89 | Upgrade
|
| Net Income Growth | - | - | - | - | -59.11% | Upgrade
|
| Shares Outstanding (Basic) | 4,766 | 3,743 | 670 | 643 | 639 | Upgrade
|
| Shares Outstanding (Diluted) | 4,766 | 3,743 | 670 | 643 | 677 | Upgrade
|
| Shares Change (YoY) | 27.33% | 458.41% | 4.26% | -4.98% | 0.47% | Upgrade
|
| EPS (Basic) | -0.01 | -0.01 | -0.06 | -0.02 | 0.00 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.01 | -0.06 | -0.02 | 0.00 | Upgrade
|
| EPS Growth | - | - | - | - | -59.06% | Upgrade
|
| Free Cash Flow | -31.37 | -35.54 | -33.55 | -17.06 | 6.03 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.05 | -0.03 | 0.01 | Upgrade
|
| Gross Margin | 53.23% | 53.87% | 55.79% | 68.03% | 73.79% | Upgrade
|
| Operating Margin | -51.75% | -62.20% | -59.05% | -17.00% | 4.66% | Upgrade
|
| Profit Margin | -72.91% | -69.97% | -72.28% | -18.93% | 3.42% | Upgrade
|
| Free Cash Flow Margin | -57.00% | -64.38% | -56.30% | -23.44% | 7.15% | Upgrade
|
| EBITDA | -26.18 | -32.17 | -33.08 | -10.24 | 6.11 | Upgrade
|
| EBITDA Margin | -47.56% | -58.27% | -55.51% | -14.07% | 7.25% | Upgrade
|
| D&A For EBITDA | 2.31 | 2.17 | 2.11 | 2.13 | 2.19 | Upgrade
|
| EBIT | -28.49 | -34.34 | -35.19 | -12.37 | 3.93 | Upgrade
|
| EBIT Margin | -51.75% | -62.20% | -59.05% | -17.00% | 4.66% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 21.08% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.